NOVA1 (E9E6U) Rabbit mAb #65350
- WB
- IP
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 58 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
Storage
Protocol
Specificity / Sensitivity
NOVA1 (E9E6U) Rabbit mAb recognizes endogenous levels of total NOVA1 protein. This antibody does not cross-react with NOVA2 protein. This antibody detects an 85 kDa band of unknown origin.
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala36 of human NOVA1 protein.
Background
Neuro-oncological ventral antigen (NOVA) 1 and 2 are neuronal RNA-binding proteins (RBPs) that bind YCAY motifs to regulate alternative splicing (1-3). Both proteins have been shown to be targets in paraneoplastic opsoclonus myoclonus ataxia, a neuronal autoimmune disease (1,3). NOVA proteins rely on their KH3 domain to bind RNA and are reciprocally expressed in various parts of the brain (4). NOVA1 has been shown to be essential for neuronal viability, as it controls alternative splicing in GlyRalpha2 and GABA(A) receptor pre-mRNAs (5). NOVA1 is also capable of auto-regulation as it binds to its own exon 4, which contains a phosphorylated protein domain (6). NOVA1/2 double knockout mice are paralyzed due to lack of alternatively spliced agrin Z(+), which helps synapse formation at neuromuscular junctions (7). NOVA2 has been shown to regulate circular RNA biogenesis in the developing brain (8). NOVA1 has been shown to be highly expressed in many different cancer types, and can promote epithelial-mesenchymal transition by binding β-catenin mRNA (9,10).
- Buckanovich, R.J. et al. (1996) J Neurosci 16, 1114-22.
- Buckanovich, R.J. and Darnell, R.B. (1997) Mol Cell Biol 17, 3194-201.
- Yang, Y.Y. et al. (1998) Proc Natl Acad Sci U S A 95, 13254-9.
- Lewis, H.A. et al. (1999) Structure 7, 191-203.
- Dredge, B.K. et al. (2005) EMBO J 24, 1608-20.
- Ruggiu, M. et al. (2009) Proc Natl Acad Sci U S A 106, 3513-8.
- Cao, Y. et al. (2021) Mol Cell Biochem 476, 279-292.
- Knupp, D. et al. (2021) Nucleic Acids Res 49, 6849-6862.
- Liu, M. et al. (2020) Transl Cancer Res 9, 4373-4382.
- Tang, S. et al. (2020) RNA Biol 17, 881-891.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.